Apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) triggers platelet activation and boosts platelet-leukocyte proinflammatory responses

Thrombosis and Haemostasis

Volumn 112, Issue 2, 2014, Pages 332-341

  Assinger, Alice ^a,b   Wang, Yajuan ^b,c   Butler, Lynn M ^b   Hansson, Göran K ^b   Yan, Zhong Qun ^b   Söderberg Nauclér, Cecilia ^b   Ketelhuth, Daniel F J ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SHANDONG UNIVERSITY   (China)

Author keywords

ApoB; Atherosclerosis; Inflammation; LDL; Platelets

Indexed keywords

APOLIPOPROTEIN B100; CD63 ANTIGEN; LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; ADENOSINE DIPHOSPHATE; APOB PROTEIN, HUMAN; AUTACOID; CYTOKINE; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2;

ARTICLE; ATHEROSCLEROSIS; CALCIUM TRANSPORT; DENSITY GRADIENT CENTRIFUGATION; FLOW CYTOMETRY; HUMAN; INFLAMMATION; INNATE IMMUNITY; NEUTROPHIL; NORMAL HUMAN; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; SHEAR STRESS; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; WESTERN BLOTTING; ADULT; BLOOD; CELL COMMUNICATION; CELL CULTURE; COCULTURE; IMMUNOLOGY; LEUKOCYTE; METABOLISM; THROMBOCYTE; TIME; UMBILICAL VEIN ENDOTHELIAL CELL; YOUNG ADULT;

ADENOSINE DIPHOSPHATE; ADULT; APOLIPOPROTEIN B-100; BLOOD PLATELETS; CELL COMMUNICATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; PLATELET ACTIVATION; PLATELET ADHESIVENESS; RECEPTORS, PURINERGIC P2Y12; SIGNAL TRANSDUCTION; THROMBOXANE A2; TIME FACTORS; YOUNG ADULT;

EID: 84905187098     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-12-1026     Document Type: Article

References (45)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
2. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
3. Lievens D, Zernecke A, Seijkens T, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317-4327.
4. Gerdes N, Zhu L, Ersoy M, et al. Platelets regulate CD4+ T-cell differentiation via multiple chemokines in humans. Thromb Haemost 2011; 106: 353-362.
5. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005; 96: 612-616.
6. Weyrich AS, Zimmerman GA. Platelets: signalling cells in the immune continuum. Trends Immunol 2004; 25: 489-495.
7. Ketelhuth DF, Hansson GK. Cellular immunity, low-density lipoprotein and atherosclerosis: Break of tolerance in the artery wall. Thromb Haemost 2011; 106: 779-786.
8. Relou IA, Hackeng CM, Akkerman JW, et al. Low-density lipoprotein and its effect on human blood platelets. Cell Mol Life Sci 2003; 60: 961-971.
9. Engelmann B, Kogl C, Kulschar R, et al. Transfer of phosphatidylcholine, phosphatidylethanolamine and sphingomyelin from low-and high-density lipoprotein to human platelets. Biochem J 1996; 315: 781-789.
10. Relou AM, Gorter G, van Rijn HJ, et al. Platelet activation by the apoB/E receptor-binding domain of LDL. Thromb Haemost 2002; 87: 880-887.
11. Relou IA, Gorter G, Ferreira IA, et al. Platelet endothelial cell adhesion molecule-1 (PECAM-1) inhibits low density lipoprotein-induced signalling in platelets. J Biol Chem 2003; 278: 32638-32644.
12. Koller E, Koller F. Binding characteristics of homologous plasma lipoproteins to human platelets. Methods Enzymol 1992; 215: 383-398.
13. Siess W. Platelet interaction with bioactive lipids formed by mild oxidation of low-density lipoprotein. Pathophysiol Haemost Thromb 2006; 35: 292-304.
14. Hermansson A, Johansson DK, Ketelhuth DF, et al. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 2011; 123: 1083-1091.
15. Hermansson A, Ketelhuth DF, Strodthoff D, et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 2010; 207: 1081-1093.
16. Ketelhuth DF, Tonini GC, Carvalho MD, et al. Autoantibody response to chromatographic fractions from oxidized LDL in unstable angina patients and healthy controls. Scand J Immunol 2008; 68: 456-462.
17. Fredrikson GN, Hedblad B, Berglund G, et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 872-878.
18. Ketelhuth DF, Rios FJ, Wang Y, et al. Identification of a danger-associated peptide from apolipoprotein B100 (ApoBDS-1) that triggers innate proatherogenic responses. Circulation 2011; 124: 2433-2443, 1-7.
19. Havel RJ, Eeder HA, Gragdon JH. [The distribuition and chemical composition of ultracentrifugally separated lipoproteins in human serum]. J Clin Invest 1955; 34: 345-353.
20. Volf I, Bielek E, Moeslinger T, et al. Modification of protein moiety of human low density lipoprotein by hypochlorite generates strong platelet agonist. Arterioscler Thromb Vasc Biol 2000; 20: 2011-2018.
21. Assinger A, Koller F, Schmid W, et al. Specific binding of hypochlorite-oxidized HDL to platelet CD36 triggers proinflammatory and procoagulant effects. Atherosclerosis 2010; 212: 153-160.
22. Assinger A, Laky M, Schabbauer G, et al. Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2. JThrombHaemost 2011; 9: 799-809.
23. Assinger A, Schmid W, Eder S, et al. Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett 2008; 582: 778-784.
24. Butler LM, Jeffery HC, Wheat RL, et al. Kaposi's sarcoma-associated herpesvirus infection of endothelial cells inhibits neutrophil recruitment through an interleukin-6-dependent mechanism: a new paradigm for viral immune evasion. J Virol 2011; 85: 7321-7332.
25. Badrnya S, Butler LM, Soderberg-Naucler C, et al. Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein. Thromb Haemost 2012; 108: 719-729.
26. Jackson SP. Arterial thrombosis--insidious, unpredictable and deadly. Nat Med 2011; 17: 1423-1436.
27. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
28. Badrnya S, Schrottmaier WC, Kral JB, et al. Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation. Arterioscler Thromb Vasc Biol 2014; 34: 571-580.
29. Linden MD, Furman MI, Frelinger AL, 3rd, et al. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost 2007; 5: 761-765.
30. Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394: 200-203.
31. Lievens D, Zernecke A, Seijkens T, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317-4327.
32. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
33. Korporaal SJ, Gorter G, van Rijn HJ, et al. Effect of oxidation on the platelet-activating properties of low-density lipoprotein. Arterioscler Thromb Vasc Biol 2005; 25: 867-872.
34. Nergiz-Unal R, Lamers MM, Van Kruchten R, et al. Signalling role of CD36 in platelet activation and thrombus formation on immobilized thrombospondin or oxidized low-density lipoprotein. J Thromb Haemost 2011; 9: 1835-1846.
35. Chen K, Febbraio M, Li W, et al. A specific CD36-dependent signalling pathway is required for platelet activation by oxidized low-density lipoprotein. Circ Res 2008; 102: 1512-1519.
36. Li Z, Delaney MK, O'Brien KA, et al. Signalling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010; 30: 2341-2349.
37. Stojanovic A, Marjanovic JA, Brovkovych VM, et al. A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signalling pathway in stimulating platelet secretion and aggregation. J Biol Chem 2006; 281: 16333-16339.
38. Cardin AD, Witt KR, Chao J, et al. Degradation of apolipoprotein B-100 of human plasma low density lipoproteins by tissue and plasma kallikreins. J Biol Chem 1984; 259: 8522-8528.
39. Edelstein C, Nakajima K, Pfaffinger D, et al. Oxidative events cause degradation of apoB-100 but not of apo[a] and facilitate enzymatic cleavage of both proteins. J Lipid Res 2001; 42: 1664-16670.
40. Schuh J, Fairclough GF, Jr., Haschemeyer RH. Oxygen-mediated heterogeneity of apo-low-density lipoprotein. Proc Natl Acad Sci USA 1978; 75: 3173-3177.
41. Forgez P, Gregory H, Young JA, et al. Identification of surface-exposed segments of apolipoprotein B-100 in the LDL particle. BiochemBiophysResCommun 1986; 140: 250-257.
42. Pentikainen MO, Oorni K, Ala-Korpela M, et al. Modified LDL-trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 2000; 247: 359-370.
43. Bengtsson T, Karlsson H, Gunnarsson P, et al. The periodontal pathogen Porphyromonas gingivalis cleaves apoB-100 and increases the expression of apoM in LDL in whole blood leading to cell proliferation. J Intern Med 2008; 263: 558-571.
44. Pierides C, Bermudez-Fajardo A, Fredrikson GN, et al. Immune responses elicited by apoB-100-derived peptides in mice. Immunol Res 2013; 56: 96-108.
45. Nilsson J, Bjorkbacka H, Fredrikson GN. Apolipoprotein B100 autoimmunity and atherosclerosis-disease mechanisms and therapeutic potential. Curr Opin Lipidol 2012; 23: 422-428.